Skip to content
Medical Health Aged Care

Australia’s approach to musculoskeletal injury care and reimbursement demands rethink: Report

Smith & Nephew UK Ltd 8 mins read

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces a new report examining musculoskeletal injury care and reimbursement in Australia that urges health payers and providers to resolve system-wide challenges hindering positive patient pathways from primary settings through to recovery.

The Economist Impact - Musculoskeletal Injuries in Australia Report outlines the growing number of meniscal injury (MI) and rotator cuff (RC) injuries in Australia. It seeks to find solutions to ensure patients in Australia access better care for acute soft tissue injuries, and that a multi-party solution is adopted to address risks and gaps in current practices care looking at diagnostic techniques, referral mechanisms, and cost considerations of different reimbursement and/or compensation schemes.

Smith+Nephew Senior Director, Sports Medicine, Ella Post says that these injuries impact individuals, the health system and workplaces and that patient pathways need to be simplified and streamlined to ensure best-practice diagnosis and treatment.

“Our health system is experiencing heightened demand for surgical interventions for meniscal and rotator cuff injuries related services causing what we believe is a concerning and growing public health challenge in Australia. We know that access to care is dwindling, as elective surgery queues are getting bigger, and pathways are inconsistent between different clinicians and providers.

We believe it will take an all-of-system approach to ensure that Australians experiencing these injuries get the care they need, when they need it and at the quality they deserve.”

Key recommendations of the report include:

  • Increase awareness of the burden of MI and RC injuries
  • Simplify and streamline patient pathways
  • Recognise and provide support for the different roles played by healthcare professionals, especially GPs, along the patient pathway
  • Improve elements of the health system, including better access to and use of clinical data
  • Review costs and existing compensation/reimbursement schemes for MI and RC injuries

Musculoskeletal disorders are the biggest contributor to years lived with disability worldwide (approximately 17%)1. If left unresolved, MI and RC injuries can lead to severe difficulties in performing activities of daily living, work-related disruption, social withdrawal, and emotional distress.

While it is recognised that the impact of musculoskeletal injuries is vast, and serious work-related claims for these injuries are on the rise, the report outlines the lack of data available to inform and guide clinical decisions and referral patterns.

“Many of these recommendations hinge on knowing more through better communications and data sharing. Setting up a centralised registry for MI and RC injuries would help to quantify the cost of lost productivity and reduced physical function and better inform and guide clinical decisions and referral patterns, improving the quality and timeliness of care delivered,” says Post.

The report suggests that the Australian Government does not recognise these injuries as a health priority and says that critical policy changes are needed to minimise morbidities caused by untreated meniscal and rotator cuff injuries.

Kieran Fallon, Professor, Musculoskeletal, Sport and Exercise Medicine, Australia National University Medical School says that report also found that GPs and allied health services play a critical role in ensuring an outcomes-focused patient journey with the patient pathway for these injuries varying significantly depending on GPs’ referral decisions.

“What I really like to see in terms of pathways is much better education of our GPs in two things. One is in clinical orthopaedic examinations. And second, in their access to the new and enormous amounts of data that’s coming out in this area.”

Please see the report here:


1. Cieza A, Causey K, Kamenov K, et al. Global estimates of the need for rehabilitation based on the global burden of disease study 2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2021;396(10267):2006-2017.


About Meniscal injuries and rotator cuff injuries

  • Musculoskeletal injury refers to damage of muscular or skeletal systems, usually due to a strenuous activity and includes damage to skeletal muscles, bones, tendons, joints, ligaments, and other affected soft tissues.
  • Meniscal tears are one of the most common work-related injuries, with associated risk factors such as kneeling, squatting or crouching, crawling, lifting/carrying/moving, standing up from a kneel, stair or ladder climbing, and driving.
  • Over the last 20 years, the prevalence of shoulder pain in the general population aged <70 years grew 20% while the lifetime of prevalence of shoulder pain has increased to 67%1.
  • Knee and ankle injuries constitute 13% of the total medical consultations, out of which 11 % are caused by meniscal tears2.

About the report
Musculoskeletal Injuries in Australia: Current Challenges and Opportunities is an Economist Impact report, sponsored by Smith+Nephew. The report examines the different care pathways that exist for patients with musculoskeletal injuries, particularly meniscal and rotator cuff injuries, in Australia.

This research combined an evidence review, an expert panel meeting, and several in-depth interviews. The following individuals (listed alphabetically) contributed their views, insights and time for this report:  

  • Alison Thorpe, Director, Perth Shoulder Rehabilitation; Researching Clinician, Curtin University 
  • Hugh Seward, Sports Physician, WorkSafe Victoria 
  • Kieran Fallon, Professor, Musculoskeletal, Sport and Exercise Medicine, Australia National University Medical School 
  • Mark Jacobs, Injury Management Consultant, Brisbane  
  • Mark Phillips, Manager, Clinical Services Team, Recovery, Planning & Performance Division, WorkSafe Victoria 
  • Paul Dale, Director, Policy, Medical Technology Association of Australia 
  • Peter Choong, Sir Hugh Devine Professor of Surgery, University of Melbourne  
  • Sarah Griffin, Director, MedTechnique Consulting 
  • Scott Willis, National President, Australian Physiotherapy Association 
  • Tamika Heiden, Principal & Founder, Research Impact Academy 
  • Tania Pizzari, Associate Professor, Physiotherapy, La Trobe University 

Additional quotes from contributors to the report

Quoted in the Economist Impact report, Mark Jacobs, Injury Management Consultant, Brisbane, said: “Every injury is different. No two RC injuries are the same. The cuff tear might look the same, but the person that it’s attached to is very different, and that’s where people get lost.”

Identifying the global challenge posed by MSDs, Alison Thorpe, Director, Perth Shoulder Rehabilitation, and Researching Clinician, Curtin University, commented in the Economist Impact report, “The Global Burden of Disease Study ranks MSDs as one of the biggest expenses to healthcare systems around the world.”

Quoted in the Economist Impact report, Hugh Seward, Sports Physician, WorkSafe Victoria, said: “There’s a time pressure to come to a diagnosis quickly because you’ve got a full waiting room. You’re limited to probably 10 minutes in your schedule to make the diagnosis, and sometimes the pain complaint for a shoulder or knee is not the only thing that’s presented in that 10 minutes.”

Quoted in the Economist Impact report, Sarah Griffin, Director, MedTechnique Consulting, said: “The way Medicare is set up, there are a lot of perverse incentives that can actually steer people away from the most appropriate care, especially for people who don’t have private health insurance, or can’t afford to go to a private physiotherapist. For them, it might actually be quicker to go to a surgeon because the surgeon is covered under Medicare. Those incentives that are built in may actually direct people to potentially inappropriate and more expensive care.”    

Quoted in the Economist Impact report, Peter Choong, Sir Hugh Devine Professor of Surgery, University of Melbourne, said: “The internet is probably the dominant source of information for most patients before and after seeing their healthcare provider. However, the literature tells us that neither patients nor providers are able to discern the quality of information that is available on the net.”

Identifying the challenge of RC injuries in Australia, Tania Pizarri, Associate Professor of Physiotherapy at La Trobe University, commented in the Economist Impact report, “RC injuries in Australia pose a significant burden, with about one in four people experiencing shoulder pain at some point in their lives, and about one in three people presenting with injuries or pain being referred further for physiotherapy. 50% of these patients would still be in pain six months after their first episode, indicating the chronic nature of these injuries.”      

Neeladri Verma, manager for Health at Economist Impact and editor of the report, says:
"Musculoskeletal disorders are a major cause of disability and lost work time in Australia, and knee and shoulder conditions are an important part of this burden. This study is very timely given the issues the market faces, and we hope our research findings provide insight into the steps we could be taking to improve the care pathways and catalyse meaningful change for Australians living with these conditions.”


2. Ackerman IN, Page RS, Fotis K, et al. Exploring the personal burden of shoulder pain among younger people in Australia: protocol for a multicentre cohort study. BMJ Open. 2018;8(7):e021859.

3. McGaughey I, Sullivan P. The epidemiology of knee and ankle injuries on Macquarie Island. Injury. 2003;34(11):842-846




Eddie Morton
Sandpiper Health


+61 499 700 295
Lisa McDonald
+61 484 251 191


About Smith+Nephew
Smith+Nephew is a portfolio medical technology business that exists to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 19,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2022. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit and follow us on XLinkedInInstagram or Facebook.

Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of Covid, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of Covid; economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers (including, without limitation, as a result of Covid); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of Covid); competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www., for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.

Primary Logo

More from this category

  • Government NSW, Medical Health Aged Care
  • 12/07/2024
  • 12:39
MEDIA RELEASE - Network of Alcohol & Other Drug Agencies


12 July 2024 The forthcoming NSW Drug Summit is an opportunity to shelve outdated drug policies that have failed to deliver better health andwellbeing outcomes for individuals and their families. That’s the verdict from the peak organisation for the non-government drug and alcohol sector in NSW, the Network of Alcohol and other Drugs Agencies (NADA). NADA today welcomed the Government’s confirmation the NSW Drug Summit will be held over two days in regional NSW in October, and in Sydney on 4th and 5th December, as well as consultations about the Terms of Reference and other matters ahead of this. NADA…

  • Contains:
  • Medical Health Aged Care
  • 12/07/2024
  • 09:00
National Hypertension Taskforce - Australian Cardiovascular Alliance and Hypertension Australia

Australian Hypertension Taskforce unveils Roadmap to transform high blood pressure control and reduce preventable deaths

Raised blood pressure (BP), also known as hypertension, is a ‘silent killer’ and the leading cause of death in Australia, where it contributes to more than 25,000 deaths each year. It is also the leading risk factor for death from stroke, heart disease, kidney disease, and dementia, yet 68% of Australians with hypertension are uncontrolled. In response to this pressing issue, a Call to Action was published in 2022, leading to the establishment of the National Hypertension Taskforce, launched by Mark Butler MP, Minister for Health and Aged Care. The National Hypertension Taskforce, led by the Australian Cardiovascular Alliance and…

  • Medical Health Aged Care
  • 12/07/2024
  • 00:11
AI Medi Scan

AI Medi Scan Introduces New At-Home Skin Cancer Detection Technology

AI Medi Scan is developing a device that uses artificial intelligence (AI) and fluorescence imaging to allow Australians to conduct skin cancer checks at home, aiming to alleviate the impact of dermatologist shortages.SYDNEY, July 12, 2024 (GLOBE NEWSWIRE) -- AI Medi Scan, an Australian company, is pioneering a shift in skin cancer detection with its ongoing development of advanced diagnostic technologies. Aimed at empowering individuals and integrating with broader healthcare services, AI Medi Scan's long-term goal is to revolutionise how Australians address skin health, particularly in detecting melanoma, a prevalent cancer in the region.The company's current R&D efforts are focused…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.